Drug Combo Proves Powerful Against Lung Cancer Middletown NY

A two-drug combination treatment in Middletown proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Javier Ruiz
(845) 565-9800
3141 Us Route 9w
New Windsor, NY
Javier A Ruiz, MD
(845) 561-4450
59 New Windsor Hwy Rte 32
New Windsor, NY
KONAN CHIANG, MD
(845) 342-4774
111 Maltese Drive
Middletown, NY
Najamuz Zaman, MD
845-294-8888
70 Hatfield Ln
Goshen, NY
William Landau Cheplinski, MD
845-294-8888
PO Box 809
Goshen, NY
William M Goumas
(845) 692-3111
236 Crystal Run Rd
Middletown, NY
Mark Alan Tuckfelt
(845) 294-2177
4 Harriman Dr
Goshen, NY
ROBERT DINSMORE, MD
(845) 703-6999
155 Crystal Run Road
Middletown, NY
Robbie Vinton Steinberg, MD
845-344-5455
419 E Main St
Middletown, NY
Umangi Mukesh Patel, MD
845-561-6100
611 Gidney Ave
Newburgh, NY
Data Provided by:
      

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Lung Cancer Middletown NY
Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.
- Delayed Prostate Cancer Therapy Middletown NY
- Genetic Clues for Skin Cancer Therapies Middletown NY
- Exercise for Breast Cancer Survival Middletown NY
- Fungal Infection Treatments Middletown NY
- Side Effect Of Chemotherapy Drugs Middletown NY
- Exercise for Prostate Cancer Middletown NY
- Hormone Therapy for Breast Cancer Middletown NY
- Risks for Childhood Cancer Survivors Middletown NY